1. Ozakyol, A. (2017). Global epidemiology of hepatocellular carcinoma (HCC epidemiology). Journal of gastrointestinal cancer, 48(3), 238–240.
2. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
3. Yang, J., Dvornek, N. C.,, Zhang, F., Chapiro, J., Lin, M., Abajian, A., Duncan, J. S. (2019). Hepatocellular carcinoma intra-arterial treatment response prediction for improved therapeutic decision-making. arXiv preprint arXiv:1912.00411.
4. Piasecki, P., Wierzbicki, M., Majewska, A., Kieda, C., & Narloch, J. (2021). Initial experience with novel Embocure Plus microspheres for transarterial chemoembolization (TACE) of liver metastatic colorectal cancer tumours–a clinical and in vitro study. Polish Journal of Radiology, 86, 136.
5. Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Hassan Murad, M., & Marrero, J. A. (2018). AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 67(1), 358–380.